Datapoint: Ascendis Scores Approval for First Once-Weekly Childhood GHD Drug

The FDA last week cleared Ascendis Pharma’s Skytrofa, a long-acting growth hormone, for the treatment of growth hormone deficiency (GHD) in patients weighing at least 25.4 pounds. Skytrofa is Acendis’ first FDA-approved drug, and is also the first once-weekly childhood GHD treatment. Novo Nordisk’s Norditropin is one of the most advantaged GHD therapies, holding preferred status under the pharmacy benefit for 12.8% of all covered lives, and growing to 45.0% with utilization management restrictions applied. Pfizer is also working on a once-weekly childhood GHD drug, with an FDA decision set for October.

SOURCE: MMIT Analytics, as of 8/30/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 2

Datapoint: Amgen Asks Supreme Court to Hear Repatha Case

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 1

Datapoint: United to Join Massachusetts Duals Demo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 30

Datapoint: Oscar, Emory to Offer New Health Plan in Georgia

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today